The 340B Drug Pricing Program costs patients more in the long run by moving care to hospital outpatient settings rather than physicians' offices, according to a recent analysis commissioned by the drugmaker lobby Pharmaceutical Research and Manufacturers of America.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,